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Summary An analysis of the long-term results of treatment of 3,681 patients with small cell lung cancer
(SCLC) is presented. The data were obtained from major centres in the UK who were conducting treatment
trials during the period 1978-1986 and for whom complete computer records and follow-up were available. A
total of 217 (5.9%) survived 2 years or more. Two year survival for patients presenting with limited disease
(LD) was 8.5% and for extensive disease (ED) 2.2%. Death from SCLC continued until 7 years after
diagnosis but not thereafter. At this point overall survival was 3% (3.6% LD, 1. I % ED). Survival after 2
years was not affected by initial disease extent, sex, thoracic radiotherapy or prophylactic cranial irradiation.
Death from causes other than SCLC continued throughout the period of observation. Vascular disease,
respiratory failure and second tumours were the main other causes of death. The better survival in younger
patients was mainly attributable to few deaths from these other causes. These results indicate that only a small
proportion of patients with SCLC are cured by current treatment. Although shorter term improvement in
survival has been obtained with current treatment, the poor overall long-term results support studies exploring
new approaches to cure and to palliation.
The introduction of combination chemotherapy as the princi-
ple form of treatment of small cell lung cancer (SCLC) led to
an increase in median survival and suggestions that a
significant proportion of patients might be cured (Greco et
al., 1979). In some treatment trials 2 year survival figures of
10-15% are reported for patients presenting with limited
disease, usually defined as disease confined to one
hemithorax and ipsilateral supraclavicular lymph nodes
(Ihde, 1982; Feld et al., 1987). The proportion of these
patients who are cured is not clear (Bergsagel & Feld, 1984).
A rather pessimistic picture emerges from the few published
studies of long-term survival. Davis et al. (1985) reported on
1,580 cases of SCLC in general hospital practice in Seattle
and found that only 2.4% were alive at 5 years. Osterlind et
al. (1988) in a detailed study of 874 patients treated at the
Finsen Institute in Copehagen showed that only 7.6% of all
patients were alive at 18 months and that relapse from SCLC
occurred after that time. These authors also reported an
increased death rate from second, smoking-related cancers
and vascular disease, so that overall survival at 5 years was
2.5% (Osterlind et al., 1986).
In the past 10 years many centres in the UK have carried
out treatment trials in SCLC and have developed computer
data bases for recording information. We have taken the
opportunity to carry out a national study, using data from
these trials, to determine the prognosis of SCLC as it is now
treated, to relate the prognosis to factors in the patient and
in treatment, and to determine the rate of death from other
causes in patients not dying of SCLC. This exchange of data
was facilitated by formation of the Lung Cancer Subcommit-
tee of the United Kingdom Coordinating Committee on
Cancer Research.
Methods
From the list of centres undertaking treatment trials in lung
cancer compiled by the UKCCCR, eight centres were
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identified which had computer data bases for trials which
had completed recruitment in the 8 years before 1 January
1986, and for which there were complete 2 year survival data
at 1 January 1988. Details were obtained of patients' age, sex
and disease extent, which was categorised by the criteria used
by the participating centre at entry to the study as limited (L)
or extensive (E). The staging investigations used to define
extent varied between centres and during the 8 years of the
studies. The treatment in each trial was recorded, including
the use of chemotherapy, thoracic irradiation and prophylac-
tic cranial irradiation (PCI). Table I gives the list of par-
ticipating centres, the total number of patients entering the
trials conducted by those centres, and the number of 2 year
survivors. The cause of death was determined, in the patients
surviving more than 2 years, from the trial and hospital
records and from death certificates held by the General
Register Office for Scotland and the Office of Population
Censuses and Surveys, England and Wales. Reliable inform-
ation was not available for non-fatal illnesses (such as vas-
cular accidents or second tumours) occurring during the
follow up period. In the 217 two year survivors sufficient
information was available to trace death certificate inform-
ation in 98 of 121 who died. Of the 23 missing patients the
cause of death was available from the trial or hospital
records in eight, leaving 15 of 121 patients in whom a date of
death was known but no cause attributed. Ninety-six patients
are alive at the time of this report.
Statistical methods include unadjusted log rank analysis of
survival data (Peto et al., 1977) and x2 statistic.
Results
The eight centres conducted 30 trials of treatment during this
8 year period. Some of these trials were randomised com-
parisons, others were single arms studies. Details are shown
in Table II.
Of 3681 patients entered into treatment trials, 217 (5.9%)
survived 2 or more years. The characteristics of the patients
at the point of entry into the trials are summarised in Table
III. The 2 year survival for all patients pesenting with limited
disease was 8.5% and 2.2% for extensive disease. Among the
2 year survivors 83% had limited stage disease at presenta-
tion, but only 55% of all patients had limited disease. The
mean age of the 2 year survivors was usually slightly lower
than the study population in each trial. The proportion of
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TableI Numbersofpatientsadmitted tostudiesbyeachparticipatingcentre, andoverall
proportion of patients surviving 2 years or more
Patients entered on study
Trial centre No. oftrials Total number 2 year survivors (%)
1. MRC 5 1,139 66 (5.8)
2. UCH/Brompton/LCH 6 1,058 46 (4.3)
3. Manchester 4 434 37 (8.5)
4. Midlands 1 309 19 (6.1)
5. Marsden 4 277 16 (5.7)
6. Edinburgh 3 228 16 (7.0)
7. Clatterbridge 3 122 13 (10.6)
8. Dublin 4 114 4 (3.5)
Totals 30 3,681 217 (5.9)
Table 11 The design of studies contributing patients to the analysis
Trial Thoracic No. of No. of2 year
Centre no. Design Drugs RT patients survivors
I I CT +RTvsRT CY+ ME/CCNU LD 237 16
2 CT (A) vsCT (B) CY vs CY +ME+ CCNU 68 1
3 R+CTvsCT+RT+CT CY+ME+CCNU LD 186 12
4 CTvsSELECTIVE ET+CY+ME+V LD 151 8
5 CT (A)vsCT (B) ET+CY+ME+V LD 497 29
2 1 CT+RTvsCT AD+V/CY+ME LD+ED 371 7
2 CT (A) vsCT (B) CY+V+ET _C 610 23
3 CT+ RTa CY LD 26 8
4 CT+ RT3 CY/CY +ET LDb 26 4
5 CTa AD +ET+ V/CY 18 2
6 CT+ RTP C+ ET/MEL orCY LDb 7 2
3 1 CT+ RT ME +CY LD +ED 65 6
2 CT+RTP CY+ET+ME LD+ED 122 8
3 CT+ RT8 CY +ET+ ME LD +ED 79 5
4 CT+ RTa IF+ ET LD +ED 168 18
4 1 CT (A) vs CT (B) V+AD+CY LDb 309 19
5 1 CTa CY +CC+ ME LD + ED 53 4
2 CT (A) vs CT (B) CY+ME+V 45 1
3 CTa CY/AD + ET +V LD+ EDC 122 7
4 CTa C+ ET LD 57 4
6 1 CT (A) vs CT (B) ME+CY+CC+/- LD 83 8
V+ME+CY+PR
2 CT+ RP ME + CY + ET +/-MEL LD+ EDb 97 6
3 VIN + ET +/-TCNU 48 2
7 1 CT+ RP IF+ ET LD+EDc 19 2 LDb 1
2 CTa CY +AD + V/IF+ ME+ ET 72 4
3 SURGERY+CT CY+AD+/-ET 31 7
8 1 CTP CY+AD+V - 67 3
2 CTa CY + AD + ET - 23 1
3 CTa CY - 12 0
4 SC - 12 0
aNon-randomised trials; bPCI in LD responders; CPCI in LD and ED responders. AD, adriamycin; V, vincristine; CC,
CCNU; C, carboplatin; CY, cyclophosphamide; P prednisolone; CT, chemotherapy; ET, etoposide; MEL, melphalan; RT,
thoracic radiotherapy; IF, ifosfamide; VIN, vindesine; SC, supportive care; ME, methotrexate.
Table III Numbers and characteristics of patients entered into studies, with proportions surviving 2 years
Disease extent (L:E) Mean age Male:female
Trial No. of Allpatients 2 year survivors Allpatients 2 year survivors
centre patients No. (%) No. (% oftotal) All 2 years No. (%) No. (% oftotal)
1 1139 900 (79): 239 (21) 64 (7.1) 2 (1.0) 60 56 784 (70): 355 (30) 41 (5.2): 25 (7.0)
2 1058 402 (38): 656 (62) 36 (9.0) 10 (1.5) 62 58 694 (66): 364 (34) 29 (4.2) 17 (4.7)
3 434 257 (59): 177 (41) 28 (10.9): 9 (5.1) 58 58 301 (70): 133 (30) 22 (7.3) 15 (11.3)
4 309 79 (23): 230 (77) 11(14.0): 8 (3.5) 62 60 204 (66): 105 (34) 13 (6.4): 6 (5.7)
5 277 131 (47): 146 (53) 13 (10.0): 0 (0) 62 61 187 (68): 90 (32) 9 (4.8): 7 (7.8)
6 228 118 (52): 110 (48) 11 (9.3): 5 (4.5) 63 61 142 (62): 86 (38) 9 (6.3): 7 (8.1)
7 122 89 (73): 33 (27) 13 (14.6): 0 (0) 57 61 77 (63): 45 (37) 9 (11.7): 4 (8.9)
8 114 58 (51): 56 (49) 4 (6.9): 0 (0) 63 55 Unknown 3 (-): 1 (-)
Total 3681 L 2034 (55) 180 (8.5) M 2388 (67) 135 (5.7)
E 1,647 (45) 37 (2.2) F 1178 (33) 82 (7.0)586 R.L. SOUHAMI & K. LAW
men and women surviving 2 years was not significantly
different from the proportion entering the trials. The propor-
tion of patients with limited or extensive disease treated was
largely determined by the study design. For example, the
majority of the MRC studies during this period were in
patients categorised as having limited stage disease but the
London group (group 2) included limited and extensive stage
patients in their studies. Table IV gives the distribution of
patients treated with chemotherapy and radiotherapy accord-
ing to trial centre and disease extent. It can be seen that there
is wide distribution of types of treatment between the centres
so that the analysis ofeffects of treatment on survival are not
dependent on the results of one or two very large trials.
The causes of death are shown in Table V. The majority of
patients died from recurrent SCLC but 29 patients died from
other diseases of which vascular disease and other respiratory
disorders were the commonest. The cause of death is un-
known in 15. Only three patients were recorded as dying of a
second cancer, and leukaemia was not reported as a cause of
death. However, a second cancer was reported in eight
patients surviving more than 2 years, of which five were
smoking-related (Table VI).
The survival analysis is presented from 2 years onwards
and is expressed in two ways. The first includes all deaths
(SCLC, other causes of death and unknowns), and the
second deaths from SCLC alone where the few patients who
died of unknown cause are removed and the curves are cen-
sored for deaths other than SCLC. Both analyses give very
similar results. Overall survival is shown in Figure la. Figure
lb shows death from SCLC alone and Figure 2 non-SCLC
causes of death. At 6 years 45% of the 2 year survivors are
alive (3% of all patients). Death from SCLC (Figure 2) ceases
at 7 years and patients can be considered cured beyond this
point. The hazard of death from other causes (Figure 2)
continues throughout the period of observation. Although a
greater proportion of patients presenting with limited disease
survived to 2 years, beyond 2 years survival was not statis-
tically different in patients initially staged as limited or exten-
sive (Figure 3a and b). Patients below the age of 55 at
diagnosis had a slightly greater chance of survival beyond 2
years (Figure 4a) but this was not significant statistically and
was in part due to a lesser risk ofdeath from other causes and
the risk of dying from SCLC alone is only slightly influenced
by age (Figure 4b). Female sex was not associated with im-
proved survival beyond 2 years (Figure 5a and b). Patients
who were treated with thoracic radiotherapy did not have an
increased chance of survival beyond 2 years (Figure 6a and b).
There was a tendency for patients treated with prophylactic
cranial irradiation to have a slightly better prognosis after 2
Table IV Treatment modality used in the trials according to disease
extent, with proportion surviving 2 years
Chemotherapy Chemotherapy +
alone thoracic radiation
Trial Total no.
centre ofpatients No. 2 year (%) No. 2 year (%)
I. L 900 54 0 846 64(8)
E 239 239 2(1) 0 0
2. L 402 302 17(6) 100 19(19)
E 656 540 7(1) 116 3(3)
3. L 257 0 0 257 28(11)
E 177 99 3(3) 78 6(8)
4. L 79 0 0 79 11(14)
E 230 230 8(3) 0 0
5. L 131 99 7(7) 32 6(19)
E 146 128 1(<1) 18 2(1)
6. L 118 101 7(7) 17 4(23)
E 110 106 4(4) 4 1(25)
7. L 89 69 8(12) 20 5(25)
E 33 27 0 6 0
8. L 58 58 4(7) 0 0
E 56 56 0 0 0
Totals L 2034 683 43(6) 1351 137(10)
E 1647 1425 25(2) 222 12(5)
Table V Causes ofdeath in the 217 two year survivors
Number of
Causes ofdeath patients
1. Small cell lung cancer 77
2. Vascular disease
Myocardial 6
Cerebral 5
3. Second cancer 3
4. Respiratory failure 12
5. Other 3
6. Unknown 15
7. Alive 96
Total number 217
Table VI New malignancies in the 217 two year survivors
No. ofmonthsfrom
Diagnosis start ofchemotherapy Sex Dead/alive
Basal cell carcinoma 60 M A
Carcinoma of the bladder 60 M D
Carcinoma of the bladdera 48 F D
Squamous cell carcinoma lunga 43 M D
Carcinoma of larynx 36 M A
Carcinoma of breast 34 F D
Carcinoma of colona 32 F D
Carcinoma of pancreas 31 M D
aPrimary cause of death.
years (Figure 7a) but this was not apparent when SCLC
deaths alone were considered (Figure 7b). Treatments were not
of course assigned randomly in the whole population and any
relation to prognosis may of course be due to bias in selecting
cases for treatment.
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Figure 1 Survival from 2 years. a, All causes of death included
(n = 217). b, Deaths from SCLC alone (unknowns removed,
death from non SCLC causes censored: n = 199).LONGEVITY IN SCLC 587
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Figure 3 Survival from 2 years related to initial disease extent. a,
All causes of death included. Limited disease, L (n = 180). Exten-
sive disease, E (n = 37). P = 0.423. b, Deaths from SCLC alone
(censored for non-SCLC causes and patients with unknown cause
of death removed from the analysis). Limited disease, L
(n = 163). Extensive disease, E (n = 36). P = 0.772.
Discussion
We believe this analysis gives a broadly accurate assessment
of the results of contemporary treatment of SCLC in major
trials centres in the UK. The proportions of all patients
surviving at 2 and 6 years (5.9% and 3%) are identical with
those reported by Osterlind et al. (1986) and Davis et al.
(1985). Relapse and death from SCLC occurs beyond 2 years
and reported 2 year survival data should not be regarded as
indicating cure rate. Patients in treatment trials in SCLC (for
2 i -4
Figure 4 Survival from 2 years related to age at diagnosis. a,
Including all causes of death. A, < 55 years (n = 72); B, 56-65
years (n = 96); C>66 years (n = 47). (A vs C, P = 0.031; P value
for trend = 0.024). b, Deaths from SCLC alone (censored for non
SCLC causes and patients with unknown cause ofdeath removed
from the analysis). A, <55 years (n = 67); B, 56-65 years
(n = 86); C, >66 years (n = 44). No significant difference in any
comparison.
example those assessing the value of thoracic or cranial
irradiation) should be followed for a minimum of 5 years to
assess impact on long-term survival. Beyond this point death
from SCLC is uncommon.
The survival data presented here, although demonstrating
the bad long-term prognosis of the disease, do not indicate
that treatment is not worthwhile. Some patients, mostly those
with limited disease, are cured, albeit only a small number.
This implies that a large number of patients were nearly
cured by current treatment and justifies, and should
encourage, trials of treatment strategies in that category of
patients in whom cure is a realistic aim. These are mostly
patients with limited disease. Other studies (Souhami et al.,
1985) have shown the additional importance of factors such
as performance status and biochemistry in identification of
patients with an increased chance of survival at 2 years.
It must be stressed that the data concern survival beyond
two years. Other studies have shown the benefit of
chemotherapy on median and one year survival (Ihde, 1984).
The effect of thoracic irradiation on survival before 2 years is
more controversial and may be influenced by dose and timing
of treatment. It seems probable that there is a modest benefit
in patients with limited disease (Perry et al., 1987). The
present data suggest that even if patients receiving thoracic
radiation are more likely to reach 2 years, the impact of
thoracic radiotherapy on survival beyond 2 years is minimal.
Treatment trials in limited disease, which do not include
thoracic irradiation, still seem justified so far as long-term
survival is concerned. The same is true for the use of pro-
phylactic cranial irradiation (PCI). Only long-term results of588 R.L. SOUHAMI & K. LAW
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Figure 5 Survival related to sex. a, All causes of death included.
Female, F (n = 83). Male, M (n = 134). P = 0.671. b, Deaths
from SCLC alone (censored for non SCLC causes and patients
with unknown cause of death removed from the analysis).
Female, F (n = 75). Male, M (n = 124). P= 0.940.
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Figure 7 Survival related to prophylactic cranial irradiation
(PCI). a, All causes of death. PCI + (n = 52). PCI - (no PCI,
n = 165). P = 0.163. b, Deaths from SCLC alone (censored for
non SCLC causes and patients with unknown cause of death
removed from the analysis). PCI + (n = 52). PCI - (n = 147).
P= 0.313.
very large randomised studies can ultimately show the effect
of these measures, if any, but it is clearly likely to be small.
The findings indicate that for the vast majority of patients
treatment is palliative, with only 2.2% of patients with exten-
sive disease (who constitute 70% of unselected cases) surviv-
ing 2 years. For most of these patients chemotherapy
undoubtedly provides effective palliation of symptoms and
will prolong short-term survival. Long-term toxicity of
measures such as thoracic radiation and PCI was not
recorded in the trial follow-up data.
Beyond 6 years other smoking-related diseases become the
major cause of death, particularly chronic bronchitis, vas-
cular disease and smoking-related cancer. We have not found
any case of leukaemia. The accuracy of death certification
may be at fault here, but it is noteworthy that very few
studies used CCNU or procarbazine while these drugs have
been used in most of the cases where acute leukaemia has
occurred following SCLC treatment (Pedersen-Bjergaard et
al., 1986).
This survey indicates that cure is possible in SCLC but
that we have a long way to go to improve results. Given the
present results with conventional treatment, trials of novel
and intensive treatments to increase cure rate are fully
justified. Similarly, assessment of palliative regimens is an
important area of futher study. Treatment trials should pres-
Figure 6 Survival related to thoracic radiotherapy. a, All causes
of death included. RT +, thoracic radiotherapy (n = 149). RT-,
no thoracic radiotherapy (n = 68). P = 0.236. b, Deaths from
SCLC alone (censored for non SCLC causes and patients with
unknown cause of death removed from the analysis). RT +
(n = 135). RT- (n = 64). P = 0.355.
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ent 5 year survival data before claiming a benefit in long-
term survival or cure rate. Beyond this point death from
We are most grateful to the following for providing us with the
information on which this report is based. Medical Research Coun-
cil: Dr David Girling, Mr Richard Stephens; Wythenshawe Hospital:
Dr Nicholas Thatcher, Ms Linda Ashcroft; Midlands: Dr Michael
Cullen, Ms Charlotte Woodroffe, Dr David Morgan; Royal Marsden
SCLC is very uncommon and the 5 year survival figure is a
fairly accurate estimate of cure rate.
Hospital: Dr Ian Smith, Ms Julia Woodiwiss; Western General
Hospital. Edingburgh: Professor John Smyth, Ms Moira Stewart;
Clatterbridge Hospital: Dr John Green, Dr Simon Watkin; St James'
Hospital and Permount Hospital, Dublin: Dr P.A Daly.
References
BERGSAGEL, D. & FELD, R. (1984). Small cell lung cancer is still a
problem. J. Clin. Oncol., 2, 1189.
DAVIS, S., WRIGHT, P.W., SCHULMAN, S.F., SCHOLES, D., THORN-
ING, D. & HAMMAR, S. (1985). Long-term survival in small cell
carcinoma of the lung: a population experience. J. Clin. Oncol., 3,
80.
FELD, R., EVANS, W.K., COY, P. & 6 others (1987). Canadian mul-
ticenter randomised trial comparing sequential and alternating
administration of two non-cross-resistant chemotherapy combina-
tion in patients with limited small cell carcinoma of the lung. J.
Clin. Oncol., 5, 1401.
GRECO, F.A., RICHARDSON, R.L. & OLDHAM, R.K. (179). Small cell
lung cancer: complete remission and improved survival. Am. J.
Med., 66, 625.
IHDE, D.C. (1984). Current status of therapy for small cell carcinoma
of the lung. Cancer, 54, 2722.
OSTERLIND, K., HANSEN, H.H., HANSEN, M. & DOMBERNOWSKY,
P. (1986). Mortality and morbidity in long-term surviving patients
treated with chemotherapy with or withour irradiation for small
cell lung cancer. J. Clin. Oncol., 4, 1044.
PEDERSEN-BJERGAARD, J., OSTERLIND, K., HANSEN, M. et al.
(1986). Secondary malignancies following intensive chemotherapy
of small cell carcinoma of the lung. Blood, 66, 1393.
PERRY, M.C., EATON, W.L., PROPERT, K.J. & 9 others (1987).
Chemotherapy with or without radiation therapy in limited stage
small cell carcinoma of the lung. N. Engl. J. Med., 316, 912.
PETO, R., PIKE, M.C., ARMITAGE, P. et al. (1977). Design and
analysis of randomized clinical trials requiring prolonged obser-
vation of each patient. II. Analysis and examples. Br. J. Cancer,
35, 1.
SOUHAMI, R.L., BRADBURY, I., GEDDES, D.M., SPIRO, S.G.,
HARPER, P.G. & TOBIAS, J.S. (1985). Prognostic significance of
laboratory parameters measured at diagnosis in small cell car-
cinoma of the lung. Cancer Res., 45, 2878.